Susan G. Komen Pushes for Decade-Long Extension of Breast Cancer Research Stamp
Event summary
- Susan G. Komen supports the Breast Cancer Research Stamp Reauthorization Act of 2026, introduced by bipartisan legislators to extend the stamp's funding mechanism for another decade.
- The stamp has raised nearly $100 million for breast cancer research since its inception, funding projects on environmental exposures, metastatic disease predictions, and biomarker identification.
- Authorization for the stamp is set to expire at the end of 2027, and the reauthorization would secure funding through 2037.
- Breast cancer affects 1 in 8 women and 1 in 1,000 men in the U.S., with nearly 43,000 deaths expected in 2026.
The big picture
The reauthorization of the Breast Cancer Research Stamp underscores the critical role of bipartisan legislation in sustaining long-term funding for medical research. With breast cancer affecting a significant portion of the population and the stamp having raised nearly $100 million over nearly three decades, the continuation of this funding mechanism is pivotal for advancing lifesaving discoveries. The public-private partnership model demonstrated by the stamp highlights a scalable approach to funding research in areas of national interest.
What we're watching
- Legislative Momentum
- Whether Congress will swiftly pass the reauthorization bill before the current authorization expires at the end of 2027.
- Funding Impact
- How the continued funding from the stamp will affect the pace of breakthroughs in breast cancer research and treatment.
- Public-Private Partnerships
- The effectiveness of public-private partnerships in driving biomedical research, particularly in areas with high national interest.